Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALIM: teclistamab plus autologous lymphocyte infusion for relapsed/refractory multiple myeloma
2025-521827-61-00Phase 2Authorised
- Sponsor
- GIMEMA
- Start
- Jul 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of teclistamab and autologous lymphocyte infusion in multiple myeloma (MM), sponsored by GIMEMA. Primary endpoint: Duration of response. Planned start Jul 2026; status: authorised.
02
Drugs
teclistamabautologous lymphocyte infusion
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2025-521827-61-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521827-61-00.